Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) Short Interest Update

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) was the target of a significant increase in short interest in July. As of July 31st, there was short interest totaling 126,080 shares, an increase of 424.7% from the July 15th total of 24,029 shares. Currently, 5.3% of the shares of the stock are sold short. Based on an average daily volume of 6,655,441 shares, the short-interest ratio is presently 0.0 days.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on LABT. Weiss Ratings initiated coverage on Lakewood-Amedex Biotherapeutics in a research note on Monday, July 20th. They issued a “sell (e-)” rating on the stock. Wall Street Zen downgraded Lakewood-Amedex Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Lakewood-Amedex Biotherapeutics has a consensus rating of “Sell”.

Lakewood-Amedex Biotherapeutics Price Performance

Shares of LABT stock traded up $0.01 during trading on Wednesday, hitting $2.37. 63,842 shares of the stock traded hands, compared to its average volume of 1,339,024. Lakewood-Amedex Biotherapeutics has a 52-week low of $1.66 and a 52-week high of $98.20. The company has a market capitalization of $5.62 million and a price-to-earnings ratio of -1.19. The firm’s fifty day moving average price is $3.63.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) last released its quarterly earnings results on Friday, May 22nd. The company reported ($2.00) earnings per share (EPS) for the quarter. On average, equities analysts forecast that Lakewood-Amedex Biotherapeutics will post 2.52 earnings per share for the current year.

About Lakewood-Amedex Biotherapeutics

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.